Introduction: Subcutaneous implantable cardioverter defibrillators (S-ICD) are an attractive option over traditional transvenous devices as they avoid vascular complications, use less fluoroscopy, and avoid intra-cardiac leads. Their availability is increasing globally and we present our experience in North Queensland. Methods: We performed a retrospective review of patients who had an S-ICD inserted in Townsville Hospital. Hospital records and implant details were reviewed. Results: 12 patients had S-ICD implantation between January 2015 and February 2017. Mean age of 42(18-66), with 8 males. Indications included hypertrophic cardiomyopathy (3/12), channelopathies (3/12), idiopathic cardiomyopathy (3/12), ischaemic (2/12) and non-compaction cardiomyopathy (1/12). 7/12 were for primary and 5/12 for secondary prevention. All patients had QRS durations <120ms, no documented bradycardia, and an average LVEF of 46%. All procedures were done under GA using a 3-incision technique with 10 patients having satisfactory defibrillator threshold (DFT) testing. In two, DFT were contraindicated from the presence of intra-cardiac thrombus. Mean procedure time was 87mins (95%CI 53-121mins), with an average radiation dose of 20mGr. There were no peri-procedural complications and all were discharged within 48 hours post implantation. At an average of 9 months follow-up, there were no device related events, one traumatic dehiscence requiring pocket revision, one ED presentation with implantation site pain and no deaths. Conclusion: S-ICD is a safe and viable treatment for prophylaxis against sudden cardiac death. Our experience reveals excellent patient outcomes and support current evidence for its increasing use in a variety of cardiac diseases for the North Queensland community.